Hans Grossniklaus, MD, MBA

Hans E. Grossniklaus, MD, MBA was born in Massillon, Ohio. He graduated from Miami University, then received his MD degree from the Ohio State University, followed by residencies in ophthalmology and pathology at Case Western Reserve University, fellowships in ophthalmic pathology at the Wilmer Institute and the Armed Forces Institute of Pathology and ocular oncology training at Emory University. He is board certified in ophthalmology and pathology and received an MBA at Emory.

He has been on the faculty at Emory where he is the F. Phinizy Calhoun Jr. Professor and Professor of Ophthalmology and Pathology. He has been director of the L.F. Montgomery Laboratory since 1989 where he has evaluated over 50,000 cases and is the founding director of the oncology/pathology service where he sees patients and performs surgery. His research fields of interest are the pathobiology of choroidal neovascularization, the mechanisms of metastasis of uveal melanoma to the liver, and microtechnology for the control of ocular tumors.

He has received the Emory Teacher Scholar Award, Heed Award for outstanding former Heed fellow, American Academy of Ophthalmology (AAO) Senior Achievement Award, W. R. Green Lecture Award from the Macula Society, Research to Prevent Blindness Senior Scientific Investigator Award, ARVO Silver Fellow Inaugural Class, Zimmerman Medal from the American Association of Ophthalmic Oncologists and Pathologists (AAOOP), and will deliver the 2014 Jackson Memorial Lecture at the AAO. He is the President of the AAOOP. He has served on the Thesis Committee and the Council of the AOS and is currently serving as President of the AOS during its 150th Anniversary Meeting. He has authored over 400 papers in peer-reviewed journals and 6 books/monographs. His major research contributions include publications about the pathobiology of choroidal neovascularization (CNV) including the identification of vascular endothelial growth factor (VEGF) production by macrophages in CNV, creation of an animal model of ocular melanoma that forms micrometastasis in the liver, demonstration of liver micrometastasis in patients with uveal melanoma, and development of microtechology for the treatment of retinoblastoma.